



Ref: Your Mail Dated: Mar 9, 2016

Date: 13th April 2016

To,

Shri Rakesh Parekh,

Sp. Assistant

Listing Compliance

BSE Ltd.

P J Towers, Dalal Street, Mumbai - 400001, India

Ref: Company Code: 526139

Sub: Revised Unaudited Financial Result for Quarter ended December 2015

Dear Sir,

With reference to your mail dated (attached) Mar 9 , 2016 regarding the discrepancies in the Financial Result submitted by the Company for the quarter ended December 2015 we are submitting the revised Financial Results.

Please note the discrepancies as per your query/ observance were as following which have been rectified.

1. Net Sales Not Tallying

There is a difference between Segment Wise Results and Unaudited Financial Results due to a miss in presenting the Sales of Rs.7, 500 in Segment wise results which resulted in Understatement of Segment revenue for the Quarter Q3'16 compared to other. Which also resulted in understatement of Segment Profits. This can be understood from below table.

Particulars	Quarter Ended 31.12.2015 (Unaudited) (Previous)	Quarter Ended 31.12.2015 (Unaudited) (Corrected)
Segment Revenue		
Diagnostic Services	4.87	4.87
Others	6.88	6.96
Total	11.75	11.83

2. Further the Segment Results are restated for all the comparative periods considering, all the expenses which are not tracked under any of the Segment Expenses, as Unallocated Expenses which results in proper presentation of loss in Segment Results (Previously due to wrong assumption we have not presented the unallocated Expenses which resulted in under Statement of Loss). This can be understood from below table.

Old Presentation:

S.No	PARTICULARS	Quarter Ended 31.12.2015 (Unaudited)	Quarter Ended 30.09.2015 (Unaudited)	Quarter Ended 31.12.2014 (Audited)	Year to date figures for the current period 31.12.2015 (Unaudited)	Year to date figures for the previous period 31.12.2014 (Unaudited)	Previous year Ended 31.03.2015 (Audited)
2	SEGMENT RESULTS (Profit /Loss Before Tax & Interst from each Segment)						
	a)Segment -A Diagnostic services	0.88	0.36	-0.20	1.45	-0.64	-3.95
	b)Segment -B Agri Division	-	-	-	-	-	-
	c) Segment-C Bulk Drugs Trading	-	-	-	-	-	-
	d)Segment-D CRO Services	-	-	-	-	-	-
	e) Segment-E API-DHA	-	-	-461.17	-	-1,420.20	-1,854.58
	f) R & D Expenses	-0.02	-0.03	-1.21	-0.17	-7.57	-9.04
	Total Segmental Result	0.86	0.34	-462.58	1.28	-1,428.41	-1,867.58
	Other Income	-	-	-	-	-	-
	Total	0.86	0.34	-462.58	1.28	-1,428.41	-1,867.58
	Less: Interest & Finance Charges	0.02	0.09	31.99	0.15	32.10	35.97
	Less:Unallocable expenses	-	-	-	-	-	-
	Exceptional items-forex fluctuation(gain)/Loss	-	-	-	-	-	-
	Total Profit/Loss Before Tax	0.84	0.25	-494.57	1.13	-1,460.51	-1,903.55

Rectified Presentation:


S.No	PARTICULARS	Quarter Ended 31.12.2015 (Unaudited)	Quarter Ended 30.09.2015 (Unaudited)	Quarter Ended 31.12.2014 (Audited)	Year to date figures for the current period 31.12.2015 (Unaudited)	Year to date figures for the previous period 31.12.2014 (Unaudited)	Previous year Ended 31.03.2015 (Audited)
2	SEGMENT RESULTS (Profit /Loss Before Tax & Interst from each Segment)						
	a)Segment -A Diagnostic services	0.88	0.20	-0.20	1.45	-0.64	-3.95
	b)Segment -B Agri Division	-	-	-	-	-	-
	c) Segment-C Bulk Drugs Trading	-	-	-	-	-	-
	d)Segment-D CRO Services	-	-	-	-	-	-
	e) Segment-E API-DHA	-	-	-	-	-	-
	f) Segment-F Other Unallocated	-714.78	-459.11	-461.17	-1,629.70	-1,420.20	-1,854.63
	g) R & D Expenses	-0.02	-0.02	-1.21	-0.17	-7.57	-9.04
	Total Segmental Result	-713.92	-458.93	-462.58	-1,628.43	-1,428.41	-1,867.62
	Other Income	-	-	-	-	-	-
	Total	-713.92	-458.93	-462.58	-1,628.43	-1,428.41	-1,867.62
	Less: Interest & Finance Charges	0.02	0.04	31.99	0.15	32.10	35.97
	Less:Unallocable expenses	-	-	-	-	-	-
	Exceptional items-forex fluctuation(gain)/Loss	-	-	-	-	-	-
	Total Profit/Loss Before Tax	-713.94	-458.97	-494.57	-1,628.58	-1,460.51	-1,903.59

[Handwritten signature]

We request you to kindly take the information on your Records and Acknowledge the Receipt.

Thanking You

For Transgene Biotek Limited

A handwritten signature in blue ink, appearing to read 'K Koteswara Rao', with a small flourish at the end.

K Koteswara Rao

Managing Director


Encl: Copy of Your mail

ANNEXURE IX TO CLAUSE 41

(Rs. In Lacs)

Standalone Statement of Assets and Liabilities		As at Period ended 31st Dec 2015	As at year ended 31st Mar 2015
		(Unaudited)	(Audited)
A EQUITY AND LIABILITIES			
1	Share Holders Fund		
	(a) Share Capital	7,577.00	7,577.00
	(b) Reserves and Surplus	8,403.23	10,237.86
	(c) Money Received against Share Warrants	-	-
	Sub Total - Share Holders' Fund	15,980.23	17,814.86
2	Share Application Money pending allotment	-	-
3	Minority Interest	-	-
4	Non-Current Liabilities		
	(a) Long Term Borrowings	626.69	626.69
	(b) Deferred Tax Liabilities (Net)	-	-
	(c) Other Long-Term Liabilities	-	-
	(d) Long-term Provisions	12,087.86	12,087.86
	Sub-Total- Non Current Liabilities	12,714.55	12,714.55
5	Current Liabilities		
	(a) Short Term Borrowings	889.75	807.20
	(b) Trade Payables	83.36	1,560.47
	(c) Other Current Liabilities	139.70	135.55
	(d) Short-term Provisions	-	-
	Sub-Total- Current Liabilities	1,112.82	2,503.22
	TOTAL EQUITY AND LIABILITIES	29,807.60	33,032.64
B ASSETS			
1	Non-Current Assets		
	(a) Fixed Assets	14,623.21	16,369.32
	(b) Goodwill on Consolidation	-	-
	(c) Non- Current Investments	9,220.10	9,220.10
	(d) Deferred Tax Assets (Net)	-	-
	(e) Long-term Loans and Advances	2,420.85	2,419.07
	(f) Other Non Current Assets	3,198.85	3,198.85
	Sub - total -Non Current Assets	29,463.01	31,207.34
2	Current Assets		
	(a) Current Investments	-	-
	(b) Inventories	6.62	6.62
	(c) Trade Receivables	161.98	1,638.91
	(d) Cash and Cash Equivalents	2.45	3.01
	(e) Short-term Loans and Advances	173.54	176.76
	(f) Other Current Assets	-	-
	Sub-total- Current Assets	344.58	1,825.30
	TOTAL ASSETS	29,807.60	33,032.64

For and on behalf of the Board of Directors



Dr K Koteswara Rao
Chairman & Managing Director
Place: Hyderabad
Date: 15/02/2016

Annexure IV to Clause 41
Reporting of Segment wise Revenue, Results and Capital Employed along with the quarterly results

S.No	PARTICULARS	Quarter Ended	Quarter Ended	Quarter Ended	Quarter Ended	Year to date	Year to date	Previous year
		31.12.2015 (Unaudited) Rs.	30.09.2015 (Unaudited) Rs.	31.12.2014 (Unaudited) Rs.	31.12.2015 (Unaudited) Rs.	31.12.2014 (Unaudited) Rs.	31.03.2015 (Audited) Rs.	
1	SEGMENT REVENUE							
	a) Segment -A Diagnostic Services	4.87	5.53	7.57	15.07	26.92	31.48	
	b) Segment -B Agri Division	-	-	-	-	-	-	
	c) Segment-C Bulk Drugs Trading	-	-	-	-	-	-	
	d) Segment-D CRO Services	-	-	-	-	-	-	
	e) Segment-E API-DHA	-	-	-	-	-	-	
	f) Segment-F Others	6.96	2.52	0.45	11.06	0.45	1.80	
	Total:	11.83	8.05	8.02	26.13	27.37	33.28	
	Less: Inter Segment Revenue	-	-	-	-	-	-	
	Net Sales/Income From Operation	11.83	8.05	8.02	26.13	27.37	33.28	
2	SEGMENT RESULTS							
	(Profit /Loss Before Tax & Interest from each Segment)							
	a) Segment -A Diagnostic services	0.88	0.20	-0.20	1.45	-0.64	-3.95	
	b) Segment -B Agri Division	-	-	-	-	-	-	
	c) Segment-C Bulk Drugs Trading	-	-	-	-	-	-	
	d) Segment-D CRO Services	-	-	-	-	-	-	
	e) Segment-E API-DHA	-	-	-	-	-	-	
	f) Segment-F Other Unallocated	-714.78	-459.11	-461.17	-1,629.70	-1,420.20	-1,854.63	
	g) R & D Expenses	-0.02	-0.02	-1.21	-0.17	-7.57	-9.04	
	Total Segmental Result	-713.92	-458.93	-462.58	-1,628.43	-1,428.41	-1,867.62	
	Other Income	-	-	-	-	-	-	
	Total	-713.92	-458.93	-462.58	-1,628.43	-1,428.41	-1,867.62	
	Less: Interest & Finance Charges	0.02	0.04	31.99	0.15	32.10	35.97	
	Less: Unallocable expenses	-	-	-	-	-	-	
	Exceptional items-forex fluctuation(gain)/Loss	-	-	-	-	-	-	
	Total Profit/Loss Before Tax	-713.94	-458.97	-494.57	-1,628.58	-1,460.51	-1,903.59	
3	CAPITAL EMPLOYED							
	a) Segment - A Diagnostic services	324.83	324.83	324.83	324.83	324.83	324.83	
	b) Segment - B Agri Division	24,090.93	24,090.93	24,090.93	24,090.93	24,090.93	24,090.93	
	c) Segment-C Bulk Drugs	-	-	-	-	-	-	
	Total	24,415.76	24,415.76	24,415.76	24,415.76	24,415.76	24,415.76	

Place: Hyderabad
Date: 15/02/2016



TRANSGENE BIOTEK LIMITED
68,69,&70, ANRICH INDUSTRIAL AREA
BOLLARAM, MEDAK DISTRICT

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE NINE MONTHS PERIOD ENDED 31.12.2015

(Rs. In Lakhs)

Particulars	Quarter ended 31.12.2015	Quarter ended 30.09.2015	Quarter ended 31.12.2014	Year to date figures for the current period ended 31.12.2015	Year to date figures for the previous period ended 31.12.2014	For Previous year ended 31.03.2015
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1 (a) Net Sales/Income from Operations	11.83	8.05	8.02	26.13	27.37	33.28
(b) Other Operating Income	-	-	-	-	-	-
2. Expenditure						
a. Increase/decrease in stock in trade and work in progress	-	-	0.19	-	0.19	0.19
b. Consumption of raw materials	-	-	-1.67	-	1.13	1.23
2 c. Purchase of traded goods	-	-	-	-	-	-
d. Employees cost	18.01	12.85	24.19	53.28	95.65	104.21
e. Depreciation	687.68	434.95	433.04	1,550.97	1,294.42	1,718.05
f. Other expenditure	20.06	19.18	14.84	50.31	63.78	76.61
Total	725.75	466.98	470.60	1,654.55	1,455.18	1,900.29
3 Profit from Operations before Other Income, Interest and Exceptional Items (1-2)	-713.92	-458.93	-462.58	-1,628.43	-1,427.81	-1,867.02
4 Other Income	-	-	-	-	-	-
5 Profit / (loss) from Ordinary activities before finance cost and exceptional items(3+4)	-713.92	-458.93	-462.58	-1,628.43	-1,427.81	-1,867.02
6 Finance Cost	0.02	0.04	31.99	0.15	32.10	35.97
7 Profit / (loss) from ordinary activities after finance cost but before Exceptional Items (5-6)	-713.94	-458.97	-494.57	-1,628.58	-1,459.91	-1,902.99
8 Prior Period Expenses/ (income)	-	-	-	-	0.60	0.60
9 Profit (+)/ Loss (-) from Ordinary Activities before tax (7+8)	-713.94	-458.97	-494.57	-1,628.58	-1,460.51	-1,903.59
10 Tax expense	-	-	-	-	-	-
11 Net Profit (+)/ Loss (-) from Ordinary Activities after tax (9-10)	-713.94	-458.97	-494.57	-1,628.58	-1,460.51	-1,903.59
12 Extraordinary Item (net of tax expense if any)	-	-	-	-	-	-
13 Net Profit(+)/ Loss(-) for the period (11-12)	-713.94	-458.97	-494.57	-1,628.58	-1,460.51	-1,903.59
14 Share of profit/(loss) of associates	-	-	-	-	-	-
15 Minority Interest	-	-	-	-	-	-
16 Net Profit(+)/ Loss(-) after taxes, Minority interest and share of profit/(Loss) of associates (13-14-15)	-713.94	-458.97	-494.57	-1,628.58	-1,460.51	-1,903.59
17 Paid-up equity share capital (Face value of share of Rs 10/- each)	7,577.00	7,577.00	7,577.00	7,577.00	7,577.00	7,577.00
No of Shares	75,770,000	75,770,000	75,770,000	75,770,000	75,770,000	75,770,000
18 Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	8,403.23	9,421.49	12,141.45	8,403.23	12,141.45	12,141.45
Earnings Per Share (EPS)						
19 a) Basic EPS before Extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	-0.94	-0.61	-0.65	-2.15	-1.93	-2.54
b) Diluted EPS before Extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	-0.94	-0.61	-0.65	-2.15	-1.93	-2.54
c) Basic EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	-0.94	-0.61	-0.65	-2.15	-1.93	-2.54
d) Diluted EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	-0.94	-0.61	-0.65	-2.15	-1.93	-2.54
Public Shareholding						
20 No. of shares	59,342,098	59,342,098	59,342,098	59,342,098	59,342,098	59,342,098
Percentage of shareholding	78.32	78.32	78.32	78.32	78.32	78.32
Promoters and promoter group Shareholding **	16,427,902	16,427,902	16,427,902	16,427,902	16,427,902	16,427,902
a) Pledged/Encumbered	-	-	-	-	-	-
Number of shares	-	-	-	-	-	-
Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-	-
Percentage of shares (as a % of the total share capital of the company)	-	-	-	-	-	-
21 b) Non-encumbered	-	-	-	-	-	-
Number of Shares	16,427,902	16,427,902	16,427,902	16,427,902	16,427,902	16,427,902
Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00
Percentage of shares (as a % of the total share capital of the company)	21.68	21.68	21.68	21.68	21.68	21.68

Notes to the Results

- DHA Sales in powder form are to start soon in commercial quantities.
- Oral Insulin and oral delivery platform projects are proceeding well with continuing discussions with multinational companies.
- Performance of Transgene Medical Centers, the diagnostic division, has remained stagnant and the management has decided to dispose them off.
- No. of investor complaints pending at the beginning of the quarter - Nil; received during the quarter - Nil; resolved during the quarter - Nil; pending unresolved at the end of the quarter - Nil.
- The auditors have carried out a limited review of the above financial results and these were reviewed by the Audit committee and taken on record by the Board of Directors of the Company at their meeting held on 15th February 2016.
- The Company has decided to have relook at the values at which the assets of the Companies are stated in the Balance Sheet. Wherever necessary the Company will take professional help in this regard and plan to restate the assets at their real/recommended values by March 31, 2016.

Place: Hyderabad
Date: 15/02/2016

